

Philip E Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5224797/publications.pdf>

Version: 2024-02-01

147
papers

5,404
citations

117625
34
h-index

95266
68
g-index

149
all docs

149
docs citations

149
times ranked

6815
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure-Activity Relationships of Polymyxin Antibiotics. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1898-1916.	6.4	604
2	PI 3-kinase p110 β : a new target for antithrombotic therapy. <i>Nature Medicine</i> , 2005, 11, 507-514.	30.7	555
3	Pharmacology of polymyxins: new insights into an "old" class of antibiotics. <i>Future Microbiology</i> , 2013, 8, 711-724.	2.0	369
4	The major human and mouse granzymes are structurally and functionally divergent. <i>Journal of Cell Biology</i> , 2006, 175, 619-630.	5.2	187
5	A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. <i>Journal of Antibiotics</i> , 2014, 67, 147-151.	2.0	156
6	Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from <i>Porphyromonas gingivalis</i> . <i>FEBS Letters</i> , 1998, 435, 45-48.	2.8	150
7	Teaching "Old" Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative "Superbugs". <i>ACS Chemical Biology</i> , 2014, 9, 1172-1177.	3.4	139
8	The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism. <i>Cell</i> , 2016, 165, 1632-1643.	28.9	126
9	Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-Line Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. <i>ACS Infectious Diseases</i> , 2015, 1, 568-575.	3.8	124
10	The Next Generation of Phosphodiesterase Inhibitors: A Structural Clues to Ligand and Substrate Selectivity of Phosphodiesterases. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3449-3462.	6.4	121
11	The Phytosulfokine (PSK) Receptor Is Capable of Guanylate Cyclase Activity and Enabling Cyclic GMP-dependent Signaling in Plants. <i>Journal of Biological Chemistry</i> , 2011, 286, 22580-22588.	3.4	120
12	Identification of Potent Phosphodiesterase Inhibitors that Demonstrate Cyclic Nucleotide-Dependent Functions in Apicomplexan Parasites. <i>ACS Chemical Biology</i> , 2015, 10, 1145-1154.	3.4	85
13	Polymyxins: a new hope in combating Gram-negative superbugs?. <i>Future Medicinal Chemistry</i> , 2016, 8, 1017-1025.	2.3	74
14	Re-Discovering PDE3 Inhibitors - New Opportunities for a Long Neglected Target. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 421-436.	2.1	73
15	Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers. <i>British Journal of Pharmacology</i> , 2011, 164, 37-47.	5.4	72
16	Importance of the P4 α Residue in Human Granzyme B Inhibitors and Substrates Revealed by Scanning Mutagenesis of the Proteinase Inhibitor 9 Reactive Center Loop. <i>Journal of Biological Chemistry</i> , 2001, 276, 15177-15184.	3.4	68
17	The Structure of the Bacterial Oxidoreductase Enzyme DsbA in Complex with a Peptide Reveals a Basis for Substrate Specificity in the Catalytic Cycle of DsbA Enzymes. <i>Journal of Biological Chemistry</i> , 2009, 284, 17835-17845.	3.4	62
18	Structural basis of nSH2 regulation and lipid binding in PI3K β . <i>Oncotarget</i> , 2014, 5, 5198-5208.	1.8	62

#	ARTICLE	IF	CITATIONS
19	RhoA Sustains Integrin $\alpha 5 \beta 1$ Adhesion Contacts under High Shear. <i>Journal of Biological Chemistry</i> , 2002, 277, 14738-14746.	3.4	59
20	Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2311-7.	3.0	58
21	Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria. <i>Cell Chemical Biology</i> , 2018, 25, 380-391.e5.	5.2	57
22	Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. <i>BMC Neuroscience</i> , 2008, 9, S14.	1.9	56
23	Structural Determinants of Isoform Selectivity in PI3K Inhibitors. <i>Biomolecules</i> , 2019, 9, 82.	4.0	55
24	Imaging the distribution of polymyxins in the kidney. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 827-829.	3.0	54
25	Significant Accumulation of Polymyxin in Single Renal Tubular Cells: A Medicinal Chemistry and Triple Correlative Microscopy Approach. <i>Analytical Chemistry</i> , 2015, 87, 1590-1595.	6.5	54
26	A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. <i>Nature Communications</i> , 2022, 13, 1625.	12.8	53
27	Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. <i>Biochemical Journal</i> , 2008, 414, 383-390.	3.7	49
28	Evidence for the activation of PAR-2 by the sperm protease, acrosin: expression of the receptor on oocytes. <i>FEBS Letters</i> , 2000, 484, 285-290.	2.8	46
29	Synthesis, Structure-Activity Relationships and Brain Uptake of a Novel Series of Benzopyran Inhibitors of Insulin-Regulated Aminopeptidase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1368-1377.	6.4	46
30	Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxin-lipopolysaccharide binding interactions. <i>Analytical Biochemistry</i> , 2011, 409, 273-283.	2.4	45
31	Structure-activity relationships for the binding of polymyxins with human $\alpha 1$ -acid glycoprotein. <i>Biochemical Pharmacology</i> , 2012, 84, 278-291.	4.4	40
32	Identification of a unique filamin A binding region within the cytoplasmic domain of glycoprotein Ib. <i>Biochemical Journal</i> , 2005, 387, 849-858.	3.7	37
33	Isoform-Selective Inhibition of Phosphoinositide 3-Kinase: Identification of a New Region of Nonconserved Amino Acids Critical for p110 α Inhibition. <i>Molecular Pharmacology</i> , 2011, 80, 657-664.	2.3	37
34	An apically located hybrid guanylate cyclase-ATPase is critical for the initiation of Ca ²⁺ signaling and motility in <i>Toxoplasma gondii</i> . <i>Journal of Biological Chemistry</i> , 2019, 294, 8959-8972.	3.4	37
35	Molecular basis for the increased polymyxin susceptibility of <i>Klebsiella pneumoniae</i> strains with under-acylated lipid A. <i>Innate Immunity</i> , 2013, 19, 265-277.	2.4	36
36	Parallel and antiparallel cyclic peptide nanotubes. <i>Chemical Communications</i> , 2017, 53, 6613-6616.	4.1	36

#	ARTICLE	IF	CITATIONS
37	The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. <i>Cell Reports</i> , 2014, 7, 1009-1019.	6.4	34
38	In silico analysis of antibody-carbohydrate interactions and its application to xenoreactive antibodies. <i>Molecular Immunology</i> , 2009, 47, 233-246.	2.2	31
39	Discovery and antiplatelet activity of a selective PI3K β inhibitor (MIPS-9922). <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 339-351.	5.5	31
40	Comparison of the binding of α -helical and β -sheet peptides to a hydrophobic surface. <i>Chemical Biology and Drug Design</i> , 1998, 51, 401-412.	1.1	30
41	Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines. <i>European Journal of Medicinal Chemistry</i> , 2016, 110, 326-339.	5.5	30
42	Polymyxins and Analogues Bind to Ribosomal RNA and Interfere with Eukaryotic Translation in Vitro. <i>ChemBioChem</i> , 2013, 14, 2083-2086.	2.6	29
43	α -Aminoacyl-triazine Derivatives Are Isoform-Selective PI3K β Inhibitors That Target Nonconserved Asp862 of PI3K β . <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 206-210.	2.8	27
44	Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of <i>Paenibacillus polymyxa</i> ATCC 10401. <i>Journal of Natural Products</i> , 2017, 80, 1264-1274.	3.0	27
45	Definition of the binding mode of a new class of phosphoinositide 3-kinase β -selective inhibitors using <i>in vitro</i> mutagenesis of non-conserved amino acids and kinetic analysis. <i>Biochemical Journal</i> , 2012, 444, 529-535.	3.7	26
46	Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7489-7496.	3.2	26
47	Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats. <i>Journal of Natural Products</i> , 2017, 80, 225-229.	3.0	26
48	Class II Phosphoinositide 3-Kinases as Novel Drug Targets. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 47-65.	6.4	26
49	Improving Membrane Permeation in the Beyond Rule-of-Five Space by Using Prodrugs to Mask Hydrogen Bond Donors. <i>ACS Chemical Biology</i> , 2020, 15, 2070-2078.	3.4	26
50	Monoclonal antibody screening of a phage-displayed random peptide library reveals mimotopes of chemokine receptor CCR5: implications for the tertiary structure of the receptor and for an N-terminal binding site for HIV-1 gp120. <i>European Journal of Immunology</i> , 2000, 30, 1162-1171.	2.9	25
51	PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2847-2851.	2.2	25
52	Structure of granzyme C reveals an unusual mechanism of protease autoinhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5587-5592.	7.1	25
53	Identification of preferred carbohydrate binding modes in xenoreactive antibodies by combining conformational filters and binding site maps. <i>Glycobiology</i> , 2010, 20, 724-735.	2.5	25
54	A Potent Cyclic Peptide Targeting SPSB2 Protein as a Potential Anti-infective Agent. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7006-7015.	6.4	25

#	ARTICLE	IF	CITATIONS
55	Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes. <i>ACS Infectious Diseases</i> , 2017, 3, 606-619.	3.8	25
56	Structural and Biochemical Characterization of the Oxidoreductase NmDsbA3 from <i>Neisseria meningitidis</i> . <i>Journal of Biological Chemistry</i> , 2008, 283, 32452-32461.	3.4	23
57	Structure-Activity Studies of β -Hairpin Peptide Inhibitors of the <i>Plasmodium falciparum</i> AMA1-RON2 Interaction. <i>Journal of Molecular Biology</i> , 2016, 428, 3986-3998.	4.2	22
58	History, Chemistry and Antibacterial Spectrum. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 15-36.	1.6	22
59	Phenylalanine-544 Plays a Key Role in Substrate and Inhibitor Binding by Providing a Hydrophobic Packing Point at the Active Site of Insulin-Regulated Aminopeptidase. <i>Molecular Pharmacology</i> , 2010, 78, 600-607.	2.3	21
60	Imidazolidin-4-ones: Their Syntheses and Applications. <i>Heterocycles</i> , 2011, 83, 1953.	0.7	20
61	Carbohydrate-mimetic peptides: structural aspects of mimicry and therapeutic implications. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 211-224.	3.1	20
62	Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	20
63	Mechanisms of PI3K β -Selective Inhibition Revealed by Reciprocal Mutagenesis. <i>ACS Chemical Biology</i> , 2013, 8, 679-683.	3.4	19
64	Design, Synthesis, and Characterization of Cyclic Peptidomimetics of the Inducible Nitric Oxide Synthase Binding Epitope That Disrupt the Protein-Protein Interaction Involving SPRY Domain-Containing Suppressor of Cytokine Signaling Box Protein (SPSB) 2 and Inducible Nitric Oxide Synthase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5799-5809.	6.4	19
65	Synthesis of peptide amides using Fmoc-based solid-phase procedures on 4-methylbenzhydrylamine resins. <i>International Journal of Peptide and Protein Research</i> , 1995, 46, 174-180.	0.1	18
66	Thiophene inhibitors of PDE4: Crystal structures show a second binding mode at the catalytic domain of PDE4D2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7089-7093.	2.2	18
67	Transcriptomic Analysis of the Activity of a Novel Polymyxin against <i>Staphylococcus aureus</i> . <i>MSphere</i> , 2016, 1, .	2.9	18
68	Structure-Interaction Relationship of Polymyxins with the Membrane of Human Kidney Proximal Tubular Cells. <i>ACS Infectious Diseases</i> , 2020, 6, 2110-2119.	3.8	18
69	Redox-stable cyclic peptide inhibitors of the SPSB2-iNOS interaction. <i>FEBS Letters</i> , 2016, 590, 696-704.	2.8	17
70	A Cyclic Peptide Inhibitor of the iNOS-SPSB Protein-Protein Interaction as a Potential Anti-Infective Agent. <i>ACS Chemical Biology</i> , 2018, 13, 2930-2938.	3.4	17
71	Application of a Sulfoxonium Ylide Electrophile to Generate Cathepsin X-Selective Activity-Based Probes. <i>ACS Chemical Biology</i> , 2020, 15, 718-727.	3.4	17
72	A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes. <i>ACS Infectious Diseases</i> , 2016, 2, 341-351.	3.8	16

#	ARTICLE	IF	CITATIONS
73	Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y ₄ Receptor Agonist Derived by an Olefin Metathesis Approach. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6059-6069.	6.4	16
74	Disrupting the platelet internal membrane via PI3KC2Î± inhibition impairs thrombosis independently of canonical platelet activation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	16
75	Thiazolidinedione-Based PI3KÎ± Inhibitors: An Analysis of Biochemical and Virtual Screening Methods. <i>ChemMedChem</i> , 2011, 6, 514-522.	3.2	15
76	Synthesis and Pharmacological Evaluation of 4-Iminothiazolidinones for Inhibition of PI3 Kinase. <i>Australian Journal of Chemistry</i> , 2012, 65, 1396.	0.9	15
77	Quantitation of Polymyxin-B Lipopolysaccharide Interactions Using an Image-Based Fluorescent Probe. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1006-1010.	3.3	15
78	Conformational studies on (+)-anatoxin-a and derivatives. <i>Journal of Computer-Aided Molecular Design</i> , 1992, 6, 287-298.	2.9	14
79	Synthetic Studies of the Phosphatidylinositol 3-Kinase Inhibitor LY294002 and Related Analogues. <i>Australian Journal of Chemistry</i> , 2003, 56, 1099.	0.9	14
80	Structural modification of anatoxin-a. Synthesis of model affinity ligands for the nicotinic acetylcholine receptor. <i>Journal of the Chemical Society Chemical Communications</i> , 1991, , 243.	2.0	13
81	Hypoglycaemic activity of an analogue of human growth hormone [6-13] incorporating a d-ala-pro dipeptide unit. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 1625-1628.	2.2	13
82	Solid phase synthesis of cyclic peptides: model studies involving i+4 side chain-to-side chain cyclisation. , 1998, 4, 335-343.		13
83	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 802-805.	2.2	13
84	A Novel Serpin Regulatory Mechanism. <i>Journal of Biological Chemistry</i> , 2016, 291, 3626-3638.	3.4	13
85	A novel chemical biology and computational approach to expedite the discovery of new-generation polymyxins against life-threatening <i>Acinetobacter baumannii</i> . <i>Chemical Science</i> , 2021, 12, 12211-12220.	7.4	13
86	Tropane-based amino acids for peptide structure-function studies: Inhibitors of platelet aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 2699-2704.	2.2	12
87	Conformational stability of a type IIÎ²-turn motif in human growth hormone [6-13] peptide analogues at hydrophobic surfaces. <i>Chemical Biology and Drug Design</i> , 1997, 49, 394-403.	1.1	12
88	A facile, click chemistry-based approach to assembling fluorescent chemosensors for protein tyrosine kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 329-331.	2.2	12
89	IP ₃₋₄ kinase Arg1 regulates cell wall homeostasis and surface architecture to promote <i>Cryptococcus neoformans</i> infection in a mouse model. <i>Virulence</i> , 2017, 8, 1833-1848.	4.4	12
90	Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7106-7109.	2.2	11

#	ARTICLE	IF	CITATIONS
91	Potent Inhibitors of Phosphatidylinositolâ€¦3 (PI3) Kinase that have Antiproliferative Activity Only When Delivered as Prodrug Forms. <i>ChemMedChem</i> , 2013, 8, 914-918.	3.2	11
92	Propargyloxypyrrolidine Regio- and Stereoisomers for Click-Conjugation of Peptides: Synthesis and Application in Linear and Cyclic Peptides. <i>Australian Journal of Chemistry</i> , 2015, 68, 1365.	0.9	11
93	Development of single and mixed isoform selectivity PI3KÎ´ inhibitors by targeting Asn836 of PI3KÎ´. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4790-4794.	2.2	11
94	Peptide inhibitors of xenoreactive antibodies mimic the interaction profile of the native carbohydrate antigens. <i>Biopolymers</i> , 2011, 96, 193-206.	2.4	10
95	Measuring Polymyxin Uptake by Renal Tubular Cells: Is BODIPY-Polymyxin B an Appropriate Probe?. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6337-6338.	3.2	10
96	Synthetic routes to the Neuropeptide Y Y1 receptor antagonist 1229U91 and related analogues for SAR studies and cell-based imaging. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 3271-3281.	2.8	10
97	Class II but Not Second Classâ€”Prospects for the Development of Class II PI3K Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 3-6.	2.8	10
98	Synthesis of linear and angular aryl-morpholino-naphth-oxazines, their DNA-PK, PI3K, PDE3A and antiplatelet activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5534-5538.	2.2	10
99	A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4841-4856.	6.4	10
100	Synthesis of BVD15 Peptide Analogues as Models for Radioligands in Tumour Imaging. <i>International Journal of Peptide Research and Therapeutics</i> , 2013, 19, 33-41.	1.9	9
101	Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115157.	3.0	9
102	Macrocyclic peptidomimetics as inhibitors of insulin-regulated aminopeptidase (IRAP). <i>RSC Medicinal Chemistry</i> , 2020, 11, 234-244.	3.9	9
103	Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 969-973.	2.2	8
104	Identification of a Cyanine-Dye Labeled Peptidic Ligand for Y₁R and Y₄R, Based upon the Neuropeptide Y C-Terminal Analogue, BVD-15. <i>Bioconjugate Chemistry</i> , 2016, 27, 2166-2175.	3.6	8
105	Functional Characterization of the Unique Terminal Thioesterase Domain from Polymyxin Synthetase. <i>Biochemistry</i> , 2017, 56, 657-668.	2.5	8
106	Controlled Construction of Cyclic <sc>â€¦</sc>/<sc>â€¦</sc> Peptide Nanorods. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 596-601.	13.8	8
107	Synthesis and biological evaluation of a novel photo-activated histone deacetylase inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127291.	2.2	8
108	Substituted 1-methyl-4-phenylpyrrolidin-2-ones â€” Fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 191, 112120.	5.5	8

#	ARTICLE	IF	CITATIONS
109	A simple and inexpensive sample-handling method for the semi-preparative RP-HPLC of polypeptides and non-polar peptide derivatives: pre-adsorption of samples. <i>Journal of Proteomics</i> , 1995, 30, 153-161.	2.4	7
110	Fmoc-protected tropane-based amino acids for peptide structure-function studies. <i>Tetrahedron Letters</i> , 1997, 38, 2907-2910.	1.4	7
111	Conformational analysis of human growth hormone [6â€“13] peptide analogues. <i>International Journal of Peptide and Protein Research</i> , 1996, 48, 1-11.	0.1	7
112	Active site similarity between human and <i>Plasmodium falciparum</i> phosphodiesterases: considerations for antimalarial drug design. <i>Journal of Computer-Aided Molecular Design</i> , 2011, 25, 753-762.	2.9	7
113	Design and Evaluation of Novel Polymyxin Fluorescent Probes. <i>Sensors</i> , 2017, 17, 2598.	3.8	7
114	IRAP Inhibitors: M1-Aminopeptidase Family Inspiration. <i>Frontiers in Pharmacology</i> , 2020, 11, 585930.	3.5	7
115	An extensional strain sensing mechanosome drives adhesion-independent platelet activation at supraphysiological hemodynamic gradients. <i>BMC Biology</i> , 2022, 20, 73.	3.8	7
116	Synthesis of γ -aminosuccinimide-containing peptides in Fmoc-based SPPS. <i>International Journal of Peptide Research and Therapeutics</i> , 1995, 1, 263-268.	0.1	6
117	Solid-phase synthesis of a dendritic peptide related to a retinoblastoma protein fragment utilizing a combined boc- and fmoc-chemistry approach. <i>Journal of Peptide Science</i> , 2001, 7, 262-269.	1.4	6
118	Beta amino acidâ€“modified and fluorescently labelled kisspeptin analogues with potent KISS1R activity. <i>Journal of Peptide Science</i> , 2016, 22, 406-414.	1.4	6
119	(S)-(â€“)Fluorenylchloroformate (FLEC); preparation using asymmetric transfer hydrogenation and application to the analysis and resolution of amines. <i>Tetrahedron</i> , 2019, 75, 130591.	1.9	6
120	Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide. <i>Pharmaceutical Research</i> , 2021, 38, 1125-1137.	3.5	6
121	Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1185.	2.5	6
122	Synthesis of â€“Difficultâ€“Fluorescence Quenched Substrates of Granzyme C. <i>International Journal of Peptide Research and Therapeutics</i> , 2010, 16, 159-165.	1.9	5
123	(+)-Fluorenylchloroformate (FLEC) â€“ improved synthesis for application in chiral analysis and peptidomimetic synthesis. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 2571.	2.8	5
124	Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo[e][1,3]oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5531-5536.	3.0	5
125	The first total synthesis and solution structure of a polypeptin, PE2, a cyclic lipopeptide with broad spectrum antibiotic activity. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 7173-7180.	2.8	5
126	Cyclic Hexapeptide Mimics of the LEDGF Integrase Recognition Loop in Complex with HIVâ€“1 Integrase. <i>ChemMedChem</i> , 2018, 13, 1555-1565.	3.2	5

#	ARTICLE	IF	CITATIONS
127	Is There an Interplay Between the Functional Domains of IRAP?. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 585237.	3.7	5
128	Sideâ€Chain Interactions in <sc>d</sc>/<sc>l</sc> Peptide Nanotubes: Studies by Crystallography, NMR Spectroscopy and Molecular Dynamics. <i>Chemistry - A European Journal</i> , 2021, 27, 14489-14500.	3.3	5
129	Quantitative Structure-activity Relationships Of (+)-anatoxin-a Derivatives. <i>Natural Product Research</i> , 1994, 4, 121-128.	0.4	4
130	Binding Mode Prediction of PDE4 Inhibitors: A Comparison of Modelling Methods. <i>Australian Journal of Chemistry</i> , 2010, 63, 396.	0.9	3
131	Use of synthetic peptides to delineate discontinuous sequence regions involved in epitope sites of the thyrotropin Î²-subunit. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 185-192.	0.1	2
132	Solid-phase synthesis of cyclic analogues related to the hypoglycaemic peptide hGH[6-13]: Comparison of two?i+4 lactam cyclization procedures. <i>Journal of Peptide Science</i> , 2001, 7, 529-536.	1.4	2
133	A reversed-phase HPLC-based method for the assay of cyclic nucleotide phosphodiesterase activity. <i>Analytical Biochemistry</i> , 2005, 339, 185-187.	2.4	2
134	Solid Phase Synthesis and Circular Dichroism Analysis of (i â†’ÂiÂ+Â4) Cyclic Lactam Analogues of Kisspeptin. <i>International Journal of Peptide Research and Therapeutics</i> , 2008, 14, 323-331.	1.9	2
135	Discovery of Phosphodiesterase-4 Inhibitors: Serendipity and Rational Drug Design. <i>Australian Journal of Chemistry</i> , 2014, 67, 1780.	0.9	2
136	A9871 Insulin regulated aminopeptidase (irap) inhibition completely reverses age-induced cardiac fibrosis and improves cardiac function. <i>Journal of Hypertension</i> , 2018, 36, e57.	0.5	2
137	Controlled Construction of Cyclic <sc>dâ€...</sc>/<sc>â€...l</sc> Peptide Nanorods. <i>Angewandte Chemie</i> , 2019, 131, 606-611.	2.0	2
138	Heterodimeric Analogues of the Potent Y1R Antagonist 1229U91, Lacking One of the Pharmacophoric C-Terminal Structures, Retain Potent Y1R Affinity and Show Improved Selectivity over Y4R. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5274-5286.	6.4	2
139	Enhanced nitric oxide production by macrophages treated with a cell-penetrating peptide conjugate. <i>Bioorganic Chemistry</i> , 2022, 123, 105763.	4.1	2
140	Design, Development, In Vitro and Preliminary In Vivo Evaluation of a Novel Photo-Angioplasty Device: Lumi-Solve. <i>Cardiovascular Engineering and Technology</i> , 2021, 12, 466-473.	1.6	1
141	Regioselection in the synthesis of 4-benzyltetraol-1-ones and the new 4-arylbenzosuber-1-ones. <i>Tetrahedron</i> , 2021, 85, 132034.	1.9	1
142	Synthesis and biological evaluation of 4H-benzo[e][1,3]oxazin-4-ones analogues of TGX-221 as inhibitors of PI3KÎ². <i>Bioorganic and Medicinal Chemistry</i> , 2022, 69, 116832.	3.0	1
143	Title is missing!. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 185-192.	0.1	0
144	The Next Generation of Phosphodiesterase Inhibitors: Structural Clues to Ligand and Substrate Selectivity of Phosphodiesterases. <i>ChemInform</i> , 2005, 36, no.	0.0	0

#	ARTICLE	IF	CITATIONS
145	Editorial [Hot Topic : Viagras Cousins - Towards a New Generation of Phosphodiesterase Inhibitors (Guest Editor: Philip Thompson)]. Current Topics in Medicinal Chemistry, 2007, 7, 389-389.	2.1	0
146	Inflammatory Twins from PI3K Gang Brought to Justice?. Chemistry and Biology, 2010, 17, 101-102.	6.0	0
147	Novel pharmacological effects of a jungle ginger on prostate contractility. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-4-2.	0.0	0